Megan Baierlein, an experienced biopharma executive, has joined T-knife Therapeutics Inc of Germany as chief operating officer. Headquartered in Berlin with an office in San Francisco, US, T-knife is developing T cell receptor therapies for solid tumours. Ms Baierlein was most recently COO at Audentes Therapeutics Inc, a rare disease drug company. Before that, she was head of programme management at Ultragenyx Pharmaceutical Inc. She holds a bachelor of science degree in biology and kinesiology from the University of Minnesota, US.
T-knife announced the appointment on 12 July 2021.
Copyright 2021 Evernow Publishing Ltd